ADCs, mAbs, CAR Ts: One Bioluminescent Platform Measures Them All

Summary

Promega introduced the HiBiT Target Cell Killing platform, a bioluminescent assay system capable of measuring killing mechanisms across multiple immunotherapy modalities including ADCs, monoclonal antibodies, and CAR-T cells using interchangeable components.